PA
JAKK icon

PharVision Advisers’s Jakks Pacific JAKK Stock Holding History

PharVision Advisers’s Portfolio JAKK Stock Details JAKK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14,921
Closed -$279K – 847
2025
Q3 		$279K Buy
+14,921
New +$274K 0.16% 266

Other funds holding JAKK

GCCM
Gate City Capital Management Chicago, Illinois $257M AUM 37.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PRCP
Pacific Ridge Capital Partners Lake Oswego, Oregon $462M AUM 40.76% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.7B AUM 6.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GC
Gratia Capital Los Angeles, California $227M AUM 16.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PharVision Advisers's JAKK Position: Q4 2025 in Review

PharVision Advisers sold out of Jakks Pacific (JAKK) in Q4 2025, closing a stake of 14,921 shares — an estimated $279K sold.

PharVision Advisers first reported a position in JAKK in Q3 2025 and held it in 1 quarter. The position peaked at $279K in Q3 2025. 109 funds tracked by Wall St. Rank hold JAKK as of Q4 2025.

  • PharVision Advisers reported no remaining Jakks Pacific position as of Q4 2025 after selling out during the quarter.
  • PharVision Advisers sold 14,921 Jakks Pacific shares in Q4 2025, an estimated $279K.
  • PharVision Advisers first reported a position in Jakks Pacific in Q3 2025 and held it in 1 quarter.
  • PharVision Advisers's Jakks Pacific position peaked at $279K in Q3 2025.
  • 109 funds tracked by Wall St. Rank held Jakks Pacific as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.